30 Jun 16

Looking outside the BRAF gene, the researchers found the loss of tumor suppressor gene PTEN seems with patient response to GSK436, the lead researcher even more personalized approaches to melanoma therapy may help be linked.. Researchers identify genes that better predict response to BRAF inhibitors in patients with advanced melanoma CouldGenetic analysis of tumors from patients with advanced melanoma can clue researchers how well patients respond to a treatment the growth the growth-promoting protein called BRAF, a researcher from the Perelman School of Medicine at the University of Pennsylvania is the 6th on Monday In June reported at the annual meeting of the American Society of Clinical Oncology.

From the U.S. Foodan Drug Status to Reata RTA 402 for the treatment of pancreatic cancerReata Pharmaceuticals, announced that RTA 402 has granted Orphan Drug Designation by the U.S. Food and Drug Administration granted for the treatment of pancreatic cancer. RTA 402 is currently being evaluated in a Phase 1/2 trial in patients with pancreatic cancer, and is also in Phase 2 development for chronic kidney disease. – Pancreatic cancer is a devastating disease with few effective therapies, said Warren Huff, CEO of Reata. We are of the initial results with RTA 402 in pancreatic cancer encouraged and pleased that the FDA has recognized this potential by the granting of Orphan Drug status. .The University of Pennsylvania HealthSystem consists of three hospitals, which many national numerous national patient care honoring[ Hospital to the University of Pennsylvania in, Pennsylvania Hospital, the nation’s first clinic, and Penn Presbyterian Medical Center], a factorial the practice plan.

Bryan adds, If a patient is comes Penn, you can be sure that our team is on radiologists and cardiologists with the scientific expertise and clinical knowledge at the best in the best use of these new dual energy technology for excellent leading arms diagnosis and treatment of. .